Jean‐Louis Abitbol
Inventiva (France) · 42 works · 2,348 citations · h-index 17
Top works
- A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH
- Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome
- The κ agonist fedotozine relieves hypersensitivity to colonic distention in patients with irritable bowel syndrome
- Efficacy and safety of the peripheral kappa agonist fedotozine versus placebo in the treatment of functional dyspepsia
- Effect of body weight and BMI on the efficacy of levonorgestrel emergency contraception
- Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial
- Ulipristal acetate for emergency contraception: postmarketing experience after use by more than 1 million women
- A prospective, randomized, pharmacodynamic study of quick-starting a desogestrel progestin-only pill following ulipristal acetate for emergency contraception
- [Influence of rectal preparation by enema on cell proliferation in the normal rectal mucosa in man].
- Defining Survival as an Outcome Measure in Amyotrophic Lateral Sclerosis
- A phase II−III trial of olesoxime in subjects with amyotrophic lateral sclerosis
- Resetting the Abnormal Circadian Cortisol Rhythm in Adrenal Incidentaloma Patients With Mild Autonomous Cortisol Secretion
- Epithelial cell proliferation in the rectal stump of patients with ileorectal anastomosis for ulcerative colitis.
- Olesoxime (TRO19622): A Novel Mitochondrial-Targeted Neuroprotective Compound
- Specific Antinociceptive Activity of Cholest-4-en-3-one, Oxime (TRO19622) in Experimental Models of Painful Diabetic and Chemotherapy-Induced Neuropathy
- A randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non-alcoholic steatohepatitis: Design of the NATIVE study
- Translation of TRO40303 from myocardial infarction models to demonstration of safety and tolerance in a randomized Phase I trial
- Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD
- Fedotozine in irritable bowel syndrome: Results of a 6 wk placebo-controlled multicenter therapeutic trial
- Drug Discovery and Development for Spinal Muscular Atrophy: Lessons from Screening Approaches and Future Challenges for Clinical Development